glp-1 alcohol cravings GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and substance intake, though GLP-1s Hold Promise as Treatment

Nauck M, Frid A, Hermansen K, LEAD-2 Study Group, et al

A practical choice for women whose digestive health and menstrual health tend to affect each other

A physician must prescribe MOTs-C

Beneficios de Tirzepatida (agonista dual GLP-1/GIP): * Control glucmico superior: En estudios, ha demostrado reducciones de HbA1c (una medida del control del azcar en sangre a largo plazo) superiores a las observadas con agonistas del GLP-1 solos

Exercise and nutrition assist in maintaining results

From two proteomic cis-pQTL datasets, 46,650 SNPs associated with the protein expression of 1,135 druggable genes (corresponding to 803 unique proteins) were selected (Supplementary Table S2)